12/16
08:42 am
iccm
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting [Yahoo! Finance]
12/16
08:30 am
iccm
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
Medium
Report
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
12/5
08:42 am
iccm
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results [Yahoo! Finance]
Low
Report
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results [Yahoo! Finance]
12/5
08:30 am
iccm
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
Low
Report
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
11/27
01:20 pm
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Low
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
11/27
05:53 am
iccm
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/26
08:48 am
iccm
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation [Yahoo! Finance]
Low
Report
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation [Yahoo! Finance]
11/26
08:30 am
iccm
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
Medium
Report
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
11/25
08:37 am
iccm
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office [Yahoo! Finance]
Low
Report
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office [Yahoo! Finance]
11/25
08:30 am
iccm
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
Low
Report
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
11/20
08:47 am
iccm
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 [Yahoo! Finance]
Low
Report
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 [Yahoo! Finance]
11/20
08:30 am
iccm
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
Low
Report
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
11/19
08:41 am
iccm
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health [Yahoo! Finance]
Low
Report
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health [Yahoo! Finance]
11/19
08:30 am
iccm
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
Medium
Report
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
11/8
10:53 am
iccm
IceCure gets favorable FDA AdCom vote for ProSense System [Seeking Alpha]
Medium
Report
IceCure gets favorable FDA AdCom vote for ProSense System [Seeking Alpha]
11/8
07:00 am
iccm
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
High
Report
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
11/5
05:37 am
iccm
IceCure Medical Ltd (NASDAQ: ICCM) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating.
Medium
Report
IceCure Medical Ltd (NASDAQ: ICCM) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating.
10/29
08:30 am
iccm
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
High
Report
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
10/21
08:30 am
iccm
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
Medium
Report
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
10/15
05:36 pm
iccm
IceCure Medical files to sell ordinary shares and warrants [Seeking Alpha]
Medium
Report
IceCure Medical files to sell ordinary shares and warrants [Seeking Alpha]
10/7
08:15 am
iccm
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
Low
Report
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference